Bicara's Ficerafusp Alfa Plus Pembrolizumab Combo Shows Positive Data In Cancer Study, Stock Gains

(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with second-line or later squamous cancer of the anal canal or SCAC.

Among the 28 participants, the study showed a confirmed overall response rate of 25 percent with 6 partial responses and 1 complete response.

The company added that the median progression-free survival or PFS was 2.9 months and the PFS rate at one year was 40.7 percent.

Bicara highlighted that the early data indicate the crucial role of ficerafusp alfa in the future treatment of SCAC.

Currently, Bicara's stock is trading at $12.00, up 3.40 percent on the Nasdaq.